Trial Profile
An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Atezolizumab; Docetaxel; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms T-DM1 study
- Sponsors Chugai Pharmaceutical; Genentech; Roche
- 21 Jan 2022 This trial has been completed in Slovenia(End date: 2013-05-07), according to European Clinical Trials Database record.
- 21 Jan 2022 This trial has been completed in Slovenia(End date: 2013-05-07), according to European Clinical Trials Database record.
- 20 Jan 2022 This trial has been completed in Sweden, according to European Clinical Trials Database record.